Journals / Erciyes Tıp Dergisi / 2008 / Cilt: 30 - Sayı: 2

Fertility sparing options in ovarian cancers

Over kanserlerinde fertilite koruyucu yaklaşımlar

Pages
100–106
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, overviewing of the fertility sparing alternatives in patients with ovarian cancer was aimed in the light of literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the vast majority of ovarian cancers are of advanced stage and detected in postmenopausal period, a spot of them (15%) can be seen in girls or younger women.
📊
Key Findings & Data:The diagnosis of a gynecologic malignancy such as ovarian cancer can be devastating to these patients who desire future fertility.
💡
Conclusion & Impact:In this review, overviewing of the fertility sparing alternatives in patients with ovarian cancer was aimed in the light of literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although the vast majority of ovarian cancers are of advanced stage and detected in postmenopausal period, a spot of them (15%) can be seen in girls or younger women. The diagnosis of a gynecologic malignancy such as ovarian cancer can be devastating to these patients who desire future fertility. Some of these women can be candidates for fertility sparing management. Subcategories of ovarian cancers, which appropriate for this option include stage IA epithelial ovarian cancer, low malignant potential ovarian cancer, malignant germ cell tumor and sex-cord stromal tumors. Though the care of these patients is challenging and complex, we have got better alternatives than the former period. In this review, overviewing of the fertility sparing alternatives in patients with ovarian cancer was aimed in the light of literature.

Özet

Over kanserlerinin büyük çoğunluğu ileri evrede ve postmenopozal dönemde yakalanmasına rağmen, az bir kısmı (%15) genç kızlarda ya da genç kadınlarda karşımıza çıkmaktadır. Over kanseri gibi jinekolojik kanserlerin tespiti gelecekte fertilite arzusu olan bu hastalarda ümitsizliğe yol açmaktadır. Bu kadınların bir kısmı fertilite koruyucu tedaviler açısından aday olabilmektedir. Evre IA epitelyal over kanserleri, düşük malign potansiyelli over kanserleri, malign germ hücreli tümörler ve seks kord stromal tümörler bu tür yaklaşımlar açısından uygun olabilecek over kanseri alt gruplarını oluşturmaktadır. Bu tür hastaların tedavisi zor ve karmaşık olmasına rağmen, geçmiş dönemlere göre elimizde daha iyi alternatifler mevcuttur. Bu derlemede, literatür ışığında, over kanserli hastalarda kullanılabilecek fertilite koruyucu alternatiflerin gözden geçirilmesi amaçlanmıştır.

🔖

Cite This Article

ÖZÇELİK, B. (2022). Fertility sparing options in ovarian cancers. Erciyes Tıp Dergisi, Cilt: 30 - Sayı: 2, 100–106. https://ajindex.com/articles/502640

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30
  2. Leitao MM Jr, Chi DS. Fertility-sparing options for patient with gynecologic malignancies. Oncologist 2005; 10: 613-622
  3. Rodriguez M, Nguyen HN, Averette HE, et al. National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer 1994; 73: 1245-1250
  4. Duska LR, Chang YC, Flynn CE, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer 1999; 85: 2623-2629
  5. DiSaia PJ. Fertility-sparing treatment of patients with ovarian cancer. Compr Ther 1990; 16: 35-42
  6. McHale MT, DiSaia PJ. Fertility-sparing treatment of patients with ovarian cancer. Compr Ther 1999; 25: 144-150 7) Benjamin I, Morgan MA, Rubin SC. Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol 1999; 72: 288-291
  7. Morice P, Wicart-Poque F, Rey A, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001; 92: 2412-2418
  8. Zanetta G, Chiari S, Rota S, et al. Conservative surgery for stage I epithelial ovarian carcinoma in women of childbearing age. Br. J Obstet Gynecol 1997; 104: 1030- 1035
  9. Colombo N, Chiari S, Maggioni A, Bocciolone L, Torri V, Mangioni C. Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and the role of adjuvant therapy. Gynecol Oncol 1994; 55: S47-51
  10. Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001; 75: 92-96
  11. Ayhan A, Celik H, Taskiran C, Bozdag G, Aksu T. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol 2003; 24: 223-232
  12. Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility- sparing therapy. Gynecol Oncol 2002; 87: 1-7
  13. Colombo N, Parma G, Lapresa MT, Maggi F, Piantanida P, Maggioni A. Role of conservative surgery in ovarian cancer. Int J Gynecol Cancer 2005; 15: 206-211
  14. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence fort he safety and efficacy of gonodotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007; 12: 1055-1066
  15. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovaria